Related Experiment Videos
The serotonin syndrome, triptans, and the potential for drug-drug interactions
Robert E Shapiro1, Stewart J Tepper
1Department of Neurology, College of Medicine, University of Vermont, Burlington, VT, USA.
Abstract:
The serotonin syndrome is an acute adverse reaction to medications that enhance serotonergic activity. The severity of cases ranges from mild to fatal. Recently, the U.S. Food and Drug Administration issued an alert that the risk of developing serotonin syndrome may be increased by the concomitant administration of triptan medications with certain other medications. However, a review of published data does not allow an accurate assessment of such risks related to triptans. We conclude that it is currently unclear whether administration of triptans with other serotonergic medications increases the risk of serotonin syndrome.
Related Concept Videos
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Drug toxicity: Drug–Drug Interaction
Antidepressant Drugs: MAOIs and Other Agents
Drugs Affecting Neurotransmitter Release or Uptake
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...